Intellipharmaceutics

157 articles with Intellipharmaceutics

• IntelliPharmaCeutics Announces Second Quarter 2014 Results

  7/8/2014

• IntelliPharmaCeutics Files Preliminary Base Shelf Prospectus And Shelf Registration Statement

  5/21/2014

• IntelliPharmaCeutics Announces First Quarter 2014 Results

  4/14/2014

• IntelliPharmaCeutics—Amended Form Of Proxy For Shareholders Meeting To Be Held On March 27, 2014

  3/20/2014

• IntelliPharmaCeutics To Present At Two Upcoming Investor Conferences

  3/5/2014

• IntelliPharmaCeutics Announces 2013 Year End Results

  2/18/2014

• IntelliPharmaCeutics Receives $3.1 Million From Par Pharmaceutical, Inc.

  2/3/2014

• IntelliPharmaCeutics To Present At The 25th Annual Piper Jaffray Healthcare Conference

  12/2/2013

• IntelliPharmaCeutics / Par Pharmaceutical, Inc. To Make Immediate Commercial Launch Of 15 And 30 mg Generic Focalin XR®

  11/18/2013

• IntelliPharmaCeutics Announces Third Quarter 2013 Results

  10/2/2013

• IntelliPharmaCeutics Closes Public Offering for US$3.1 Million

  8/1/2013

• IntelliPharmaCeutics Announces Pricing of Public Offering of Common Shares and Warrants

  7/26/2013

• IntelliPharmaCeutics Updates Developments on Its Rexista™ Oxycodone Technology

  7/15/2013

• IntelliPharmaCeutics Announces Second Quarter 2013 Results

  7/3/2013

• IntelliPharmaCeutics Announces 2012 Year End Results

  2/1/2013

• IntelliPharmaCeutics Announces Proposed Convertible Debenture Financing

  1/7/2013

• IntelliPharmaCeutics to Ring the NASDAQ Stock Market Opening Bell

  10/26/2012

• IntelliPharmaCeutics Announces Third Quarter 2012 Results

  10/3/2012

• IntelliPharmaCeutics Achieves a 2012 Goal by Filing Two ANDAs -- Generic Forms of Keppra XR® and Pristiq®

  9/5/2012

• IntelliPharmaCeutics Settles Patent Litigation With AstraZeneca PLC Concerning Generic Seroquel XR®

  7/31/2012